MSB 3.54% $1.09 mesoblast limited

Ann: FDA Grants Orphan Drug Designation for Revascor, page-273

  1. 188 Posts.
    lightbulb Created with Sketch. 133
    Unheard of to have a trial with 19 participants show statistical signifigance easily beating .05 standard.....
    Big pharma runs trials with 5000 patients to show an overall benefit of life extension for a month that has huge side effects. And they call that a great new drug...Pfff to the drugs that dont cure,have horendous side effects and effectivness decreases quickly.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.09
Change
-0.040(3.54%)
Mkt cap ! $1.244B
Open High Low Value Volume
$1.12 $1.14 $1.09 $10.61M 9.616M

Buyers (Bids)

No. Vol. Price($)
14 241716 $1.09
 

Sellers (Offers)

Price($) Vol. No.
$1.10 1000 1
View Market Depth
Last trade - 16.10pm 09/05/2024 (20 minute delay) ?
Last
$1.10
  Change
-0.040 ( 3.00 %)
Open High Low Volume
$1.12 $1.14 $1.09 1809171
Last updated 15.59pm 09/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.